Artelo Biosciences, Inc. (ARTL) vs Aspire Biopharma Holdings, Inc. (ASBP)

A side-by-side comparison of Artelo Biosciences, Inc. and Aspire Biopharma Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARTL

Artelo Biosciences, Inc.

$1M

$3.51HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

ASBP

Aspire Biopharma Holdings, Inc.

$1M

$8.88HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ARTL vs ASBP

growth of $100 · dividends reinvested · last 4y

ARTL -99.0% (-68.4%/yr)ASBP -99.9% (-83.5%/yr)ARTL compounded faster over this window

Log scale — wide-divergence pair

ARTL ASBP

ARTL vs ASBP: by the numbers

•ARTL is the larger company ($1M vs $1M market cap).
•Both run net losses; ARTL's is the smaller (0.00% vs -11314.24% net margin).

Metrics side by side

Valuation

Metric	ARTL	ASBP
P/S ratio	N/A	10.49
P/B ratio	0.27	0.09

Profitability

Metric	ARTL	ASBP
Gross margin	0.00%	-1.87%
Operating margin	0.00%	-312016.95%
Net margin	0.00%	-11314.24%
ROE	-253.57%	-93.97%
ROIC	-219.36%	-59.81%

Growth (annualized)

Metric	ARTL	ASBP
Total return CAGR (5Y)	-64.27%	N/A

Go deeper

Full ARTL analysis Full ASBP analysis Interactive comparison tool

Dig into the metrics

Artelo Biosciences ROE Aspire Biopharma ROE Artelo Biosciences operating margin Aspire Biopharma operating margin Artelo Biosciences revenue growth Aspire Biopharma revenue growth Artelo Biosciences free cash flow Aspire Biopharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.